knowledge -WSS

knowledge

author：leisure time 2025-09-30 21:27:16 - browse：193

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Wildfire smoke exposes gaps in outdoor worker protections

WSS

Naloxone nonprofit donates 200,000 doses after FDA approval

Wegovy’s successful heart trial raises vital question about weight loss

Police still searching for prisoner who escaped from NYC hospital

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Anavex keeps shifting the goalposts in its clinical trials

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

explore

knowledge

hotspot

Affirmative action in medical school literally saved lives

Wildfire smoke exposes gaps in outdoor worker protections

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

NIH trials fail to test meaningful long Covid therapies, experts say

Continuity nursing helped my family in our darkest PICU moments

Continuity nursing helped my family in our darkest PICU moments

Activists slam private health insurers over coverage restrictions

Drug repurposing or repositioning? The language matters

Jerome Adams on the need for new antivirals for Covid

Man killed during FBI raid in connection with threats against Biden, other officials

focus

Hepatitis C has a cure — but many Americans still lack access to it

South Korea throws huge K

23andMe had bad news about my health. I wish a person had delivered it

How to save PrEP access — and even expand it

As demand for Covid shots wanes, Moderna seeks its next success

Police still searching for prisoner who escaped from NYC hospital

focus

hotspot

focus

entertainment